La cadena de opciones muestra datos clave de las opciones de acciones de Redhill Biopharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Redhill Biopharma..

Redhill Biopharma (NASDAQ:RDHL) Bolsa, Cadena de Opciones

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

RBC Capital analyst Greg Pardy maintains Strathcona Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SCR#TSX">SCR</a>) with a Sector Perform and raises the price target from C$34 to C$36.

News

Price Target

Analyst Ratings

TSX:SCR

RBC Capital Maintains Sector Perform on Strathcona Resources, Raises Price Target to C$36

WIIM

Disney shares are trading higher after the company announced it projects strong earnings growth especially in its ad supported streaming plans.

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Biogen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 26% leaning bullish and 66% bearish. Among these notable options, 2 are puts, totaling $80,703, and 13 are calls, amounting to $4,937,387.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $230.0 for Biogen, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Biogen options trades today is 1866.8 with a total volume of 4,855.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $110.0 to $230.0 over the last 30 days.
<h3>Biogen 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731688345_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$1.5M</td>
<td>8.7K</td>
<td align="right">751</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.6</td>
<td>$65.5</td>
<td>$65.5</td>
<td>$110.00</td>
<td>$1.0M</td>
<td>8.7K</td>
<td align="right">896</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.6</td>
<td>$62.5</td>
<td>$62.5</td>
<td>$110.00</td>
<td>$625.0K</td>
<td>8.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.5</td>
<td>$62.6</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$375.6K</td>
<td>8.7K</td>
<td align="right">231</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$319.2K</td>
<td>8.7K</td>
<td align="right">108</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
After a thorough review of the options trading surrounding Biogen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Biogen</h3>
<ul>
<li>Currently trading with a volume of 610,232, the BIIB's price is down by -2.38%, now at $160.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What The Experts Say On Biogen</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $219.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180. 
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $204. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $270. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Biogen, maintaining a target price of $255. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

BIIB

Biogen Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNPS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Synopsys. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $88,885, and 5 are calls, amounting to $268,163.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $670.0 for Synopsys during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Synopsys stands at 140.67, with a total volume reaching 322.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Synopsys, situated within the strike price corridor from $520.0 to $670.0, throughout the last 30 days.
<h3>Synopsys Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731688340_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$54.7</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$76.3K</td>
<td align="right">13</td>
<td align="right">18</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$41.8</td>
<td>$36.7</td>
<td>$38.0</td>
<td>$520.00</td>
<td>$61.7K</td>
<td align="right">43</td>
<td align="right">0</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$620.00</td>
<td>$46.2K</td>
<td align="right">367</td>
<td align="right">154</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$29.3</td>
<td>$28.4</td>
<td>$28.0</td>
<td>$540.00</td>
<td>$45.7K</td>
<td align="right">105</td>
<td align="right">5</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$38.1K</td>
<td align="right">13</td>
<td align="right">33</td>
</tr>
</tbody>
</table>

<h3>About Synopsys</h3>
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Having examined the options trading patterns of Synopsys, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Synopsys's Current Market Status</h3>
<ul>
<li>With a trading volume of 217,362, the price of SNPS is down by -3.59%, reaching $528.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>Expert Opinions on Synopsys</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $658.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Loop Capital downgraded its action to Buy with a price target of $675. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Synopsys with a target price of $670. 
&#x2A; In a cautious move, an analyst from Mizuho downgraded its rating to Outperform, setting a price target of $650. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $640. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Synopsys options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

SNPS

Synopsys Unusual Options Activity

Financial giants have made a conspicuous bullish move on NIO. Our analysis of options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) revealed 9 unusual trades.
Delving into the details, we found 44% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $498,343, and 4 were calls, valued at $260,650.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $17.5 for NIO, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NIO's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NIO's substantial trades, within a strike price spectrum from $3.0 to $17.5 over the preceding 30 days.
<h3>NIO Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731688335_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.97</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$5.00</td>
<td>$219.3K</td>
<td>60.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.98</td>
<td>$0.96</td>
<td>$0.97</td>
<td>$5.00</td>
<td>$153.3K</td>
<td>60.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.41</td>
<td>$1.35</td>
<td>$1.4</td>
<td>$5.00</td>
<td>$140.0K</td>
<td>51.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.05</td>
<td>$13.0</td>
<td>$13.05</td>
<td>$17.50</td>
<td>$62.6K</td>
<td>75</td>
<td>48</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.43</td>
<td>$1.41</td>
<td>$1.43</td>
<td>$5.00</td>
<td>$42.1K</td>
<td>51.2K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About NIO</h3>
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.
After a thorough review of the options trading surrounding NIO, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of NIO</h3>
<ul>
<li>Trading volume stands at 19,370,337, with NIO's price down by -0.93%, positioned at $4.39.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>What Analysts Are Saying About NIO</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $6.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Macquarie upgrades its rating to Outperform with a revised price target of $6. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for NIO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On NIO

ELAN

Elanco Acquires Speke Manufacturing Facility For $25M, Securing Critical Supply Chain For Farm Animal Products Generating $160M-$180M Annually; Expected To Impact 2025 Adjusted EBITDA By $25M-$35M

RBC Capital analyst Logan Reich reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and maintains $70 price target.

Reiteration

RBC Capital Reiterates Outperform on Chipotle Mexican Grill, Maintains $70 Price Target

COIN

Coinbase shares are trading higher after the company recently announced it acquired on-chain payments platform Utopia Labs.

Piper Sandler analyst Brian Mullan maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Neutral and raises the price target from $100 to $142.

CAVA

Piper Sandler Maintains Neutral on Cava Group, Raises Price Target to $142

Piper Sandler analyst Alexander Goldfarb maintains Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) with a Neutral and lowers the price target from $5 to $4.5.

Piper Sandler Maintains Neutral on Hudson Pacific Properties, Lowers Price Target to $4.5

RBC Capital analyst Logan Reich reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Outperform and maintains $115 price target.

SBUX

RBC Capital Reiterates Outperform on Starbucks, Maintains $115 Price Target

Zai Lab Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares are trading higher by 3.45% to $27.59 during Friday&#8217;s session. The company priced a $200 million public offering of 7,843,137 shares at <a href="https://www.benzinga.com/pressreleases/24/11/b41997659/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares">$25.50 per ADS</a>.
The offering is expected to close on November 18, subject to customary conditions. The company has also granted underwriters a 30-day option to purchase an additional 1,176,470 ADSs. 
Net proceeds will be used for general corporate purposes. Goldman Sachs, Jefferies and Leerink Partners are the joint book-running managers for the offering.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a>
<h2 class="wp-block-heading">How To Buy ZLAB Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instruments.
For example, in Zai Lab&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ZLAB has a 52-week high of $36.50 and a 52-week low of $13.48.

ZLAB

Why Zai Lab (ZLAB) Stock Is Trading Higher

Raymond James analyst Stephen Boland maintains Pollard Banknote (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBL#TSX">PBL</a>) with a Outperform and raises the price target from C$44 to C$46.

TSX:PBL

Raymond James Maintains Outperform on Pollard Banknote, Raises Price Target to C$46

Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) stock is moving lower Friday after Warren Buffet&#8216;s Berkshire Hathaway <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">cut its position in the company. </a>
What To Know: Buffet&#8217;s Berkshire Hathaway cut nearly all of its position in the beauty brand, according to Berkshire&#8217;s latest 13F filing.
Berkshire initially reported holding 690,106 shares in Ulta in an August filing. The latest 13F filing, released Thursday, shows its position has been reduced to 24,203 shares, a 96% cut.
The filing also indicates new positions in Domino&#8217;s Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>). Berkshire acquired 1,277,256 shares of Domino&#8217;s, valued at approximately $549 million, and 404,057 shares of Pool Corp, worth about $152 million.
Furthermore, the filing shows that Berkshire continued to reduce its stake in Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>). The August filing represents the company&#8217;s holdings as of June 30, while Thursday&#8217;s filing reports Berkshire&#8217;s holdings as of Sept. 30.
How To Buy Ulta Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Ulta Beauty's case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a>
ULTA Price Action: At the time of writing, Ulta stock is moving 2.39% lower at $373.24, Domino&#8217;s shares are moving 2.07% higher at $444.98, Pool stock is moving 2.52% higher at $366.51, Bank of America shares are trading 0.86% higher at $46.29, and Apple stock is moving 1.45% lower at $244.88 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Wikimedia Commons

Movers

AAPL

POOL

ULTA

What's Going On With Ulta Beauty Shares Friday?

AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are moving lower on Friday after the company reported worse-than-expected 2024 third-quarter fiscal earnings after the bell <a href="https://www.benzinga.com//node/41994523">on Thursday</a>.
What Happened: AST SpaceMobile shares fell about 13% after the company released earnings on Thursday. The earnings report included a loss of $1.10 per share, missing analyst estimates of a loss of 20 cents per share.
Furthermore, the company reported sales of $1.10 million, missing analyst estimates of $24.13 million. AST SpaceMobile reported other key pieces of financial data, including adjusted operating expenses of $45.3 million.
The company incurred about $374 million of gross capitalized property and equipment costs. It also reported $518.9 million in cash, cash equivalents and restricted cash. 
Stepping back from finances, the company announced several key agreements, such as launch service agreements with Blue Origin for launches in 2025 and 2026. These agreements will enable the orbital deployment of up to 60 Block 2 BlueBird satellites.
The company&#8217;s coverage will initially target key markets, including the U.S., Japan, and Europe.
Additionally, the company achieved initial validation of its AST5000 ASIC chip, with the necessary infrastructure in place for commissioning in 2025. The combination of the new chip and the larger Block 2 array will support enhanced data transmission.
&#8220;We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,&#8221; said Abel Avellan, founder, chairman and CEO of AST SpaceMobile. 
&#8220;With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We&#8217;ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.&#8221;
Following the earnings report, UBS analyst Christopher Schoell maintained a Buy rating on AST SpaceMobile and raised the price target from&nbsp;$30&nbsp;to&nbsp;$31.
Related Link: <a href="https://www.benzinga.com/24/11/41961161/musk-ramaswamy-headed-doge-department-will-be-an-incredibly-challenging-endeavor-says-ted-cruzshares-this-piece-o">Ted Cruz Says Running DOGE Won&#8217;t Be A Cake Walk, Offers Reading Advice To Elon Musk</a>
ASTS Price Action: At the time of publication, AST SpaceMobile shares are moving 13.8% lower at $23.11, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Company

ASTS

What's Going On With AST SpaceMobile Stock Friday?

Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Friday.</a>
The company reported fourth-quarter adjusted earnings per share of 97 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004018/spectrum-brands-holdings-reports-fiscal-2024-fourth-quarter" rel="noreferrer noopener">missing the street view of $1.07</a>. Quarterly revenues were $773.7 million (+4.5%), beating the analyst consensus of $747.51 million.
Gross profit surged 17.8% to $288 million. Gross profit and margin increased due to productivity improvements, operational efficiencies, and inventory actions in the prior year, partially offset by ocean freight inflation.
Adjusted EBITDA decreased $42.6 million, driven by $32.5 million of lower investment income and $25.9 million of increased brand-focused investments, offset by gross profit improvements.
As of the fiscal year-end, the company reported a cash balance of $369 million and total liquidity of $860 million, including undrawn capacity on its cash flow revolver.
It had $578 million in outstanding debt, consisting of $496 million in senior unsecured notes and around $82 million in finance lease obligations, resulting in a net debt of approximately $209 million.
Outlook: Spectrum Brands expects low single-digit growth in reported net sales in fiscal 2025 and adjusted EBITDA to increase by mid to high single-digits. Adjusted free cash flow is expected to be approximately<a href="https://www.benzinga.com/calendars/guidance"> 50% of adjusted EBITDA.</a>
The company continues to target a long-term net leverage ratio of 2.0 &#8211; 2.5 times.
&#8220;I am excited about the upcoming year. Our focus during fiscal 2025 will be to continue the momentum we built in fiscal 2024 by investing in our brands to drive long-term growth, in innovation to expand core and adjacent categories, and in our operations to drive further cost improvement, quality and safety,&#8221; said David Maura, Chairman and Chief Executive Officer of Spectrum Brands.
Price Action: SPB shares are trading lower by 4.78% to $89.38&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012197/totalenergies-joins-bp-equinor-and-shell-in-500m-drive-for-global-energy-access\" target="_blank" rel="noreferrer noopener">TotalEnergies Joins BP, Equinor, And Shell In $500M Drive For Global Energy Access</a></li>
</ul>

Earnings

Equities

Guidance

General

Spectrum Brands Stock Falls After Q4 Earnings Miss On Lower Investment Income: Details

Raymond James analyst Michael Barth reiterates Enerflex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFX#TSX">EFX</a>) with a Outperform and raises the price target from C$12 to C$13.75.

TSX:EFX

Raymond James Reiterates Outperform on Enerflex, Raises Price Target to C$13.75

RBC Capital analyst Matthew McKellar reiterates Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Outperform and maintains $58 price target.

RBC Capital Reiterates Outperform on Smurfit WestRock, Maintains $58 Price Target

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.&#8217;s nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.
Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.
Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.
Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.
In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;
On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.
European vaccine player stocks declined, including&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.
COVID-19 vaccine players <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.
Other vaccine players&#8217; stocks that are down include Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Inovio Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).
Price Action: GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Biotech

Large Cap

Eurozone

Health Care

Trading Ideas

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

NDRA

ENDRA Life Sciences shares are trading lower. The company reported Q3 financial results.

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has notified shareholders of amendments to its Proxy Statement related to t...

RedHill Biopharma Announces ADS Ratio Change

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced that its drug Talicia&#xAE; is now recommended as a first-line tre...

RedHill's Talicia Advances as Preferred H. pylori Treatment

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced the postponement of its Annual General Meeting of Shareholder...

RedHill Biopharma Postpones Shareholder Meeting

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. recently held its Annual General Meeting, with shareholders approving all p...

RedHill Biopharma Shareholders Approve Key Resolutions

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma Ltd. has announced a new U.S. patent for Opaganib, targeting the treatment of CO...

RedHill Biopharma Secures Opaganib COVID-19 Patent

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has renewed its contract with Medi-Cal, ensuring Talicia's continued availabilit...

RedHill Biopharma Secures Talicia's Position in Medi-Cal

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has secured funding from the U.S. government's BARDA to advance opaganib, a nove...

RedHill Biopharma Partners with BARDA for Ebola Treatment

RedHill Biopharma (RDHL) announced the signing of a collaborative research agreement with Duke University School of Medicine outlining plans for mu...

RedHill Biopharma signs research pact with Duke University School of Medicine

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has announced a collaboration with Duke University School of Medicine to test th...

RedHill Biopharma and Duke Collaborate on Opaganib Development

RedHill Biopharma (RDHL) has released an update. RedHill Biopharma has been selected to present its promising drug, Opaganib, at a U.S. government ...

Comments

Redhill Biopharma

Redhill Biopharma (RDHL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL